PE20030324A1 - Composiciones farmaceuticas de amlodipina y atorvastatina - Google Patents
Composiciones farmaceuticas de amlodipina y atorvastatinaInfo
- Publication number
- PE20030324A1 PE20030324A1 PE2002000666A PE2002000666A PE20030324A1 PE 20030324 A1 PE20030324 A1 PE 20030324A1 PE 2002000666 A PE2002000666 A PE 2002000666A PE 2002000666 A PE2002000666 A PE 2002000666A PE 20030324 A1 PE20030324 A1 PE 20030324A1
- Authority
- PE
- Peru
- Prior art keywords
- component
- atorvastatin
- alkalinizing agent
- refers
- amlodipine
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title abstract 4
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title abstract 4
- 229960005370 atorvastatin Drugs 0.000 title abstract 4
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title abstract 3
- 229960000528 amlodipine Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- -1 4-FLUOROPHENYL Chemical class 0.000 abstract 2
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract 2
- 239000001506 calcium phosphate Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229960003563 calcium carbonate Drugs 0.000 abstract 1
- 235000010216 calcium carbonate Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 abstract 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 abstract 1
- 229940038472 dicalcium phosphate Drugs 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000005469 granulation Methods 0.000 abstract 1
- 230000003179 granulation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 abstract 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 abstract 1
- 229940078499 tricalcium phosphate Drugs 0.000 abstract 1
- 235000019731 tricalcium phosphate Nutrition 0.000 abstract 1
- 238000005550 wet granulation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) UNA GRANULACION DE ATORVASTATINA O SUS SALES FARMACEUTICAMENTE ACEPTABLES Y UN VEHICULO QUE INCLUYE UN AGENTE ALCALINIZANTE QUE FORMA UN pH MAYOR A 5; b) UN SEGUNDO COMPONENTE QUE COMPRENDE AMLODIPINA O SUS SALES FARMACEUTICAMENTE ACEPTABLES Y UN VEHICULO QUE EXCLUYE UN AGENTE ALCALINIZANTE QUE FORMA pH MAYOR QUE 5 DONDE LOS DOS COMPONENTES SE COMBINAN PARA FORMAR UNA COMPOSICION FINAL PARA DAR UNA FORMA DE DOSIFICACION SOLIDA. LA COMPOSICION FARMACEUTICA DONDE EL COMPONENTE (a) ES UNA GRANULACION HUMEDA Y EL COMPONENTE (b) ES UN COMPONENTE DE POLVO SECO; Y EL AGENTE ALCALINIZANTE EN EL COMPONENTE (A) ES UN REGULADOR DE LA BIODISPONIBILIDAD Y MEJORADOR DE LA ESTABILIDAD. EL AGENTE ALCALINIZANTE SE SELECCIONA DE CARBONATO DE CALCIO, FOSFATO DE DICALCIO, FOSFATO DE TRICALCIO. LA RELACION ENTRE ATORVASTATINA Y CARBONATO DE CALCIO ES DE 1:1 A 1:4 p/p. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION . SE REFIERE TAMBIEN A UNA COMPOSICION QUE COMPRENDE AMLODIPINA, ATORVASTATINA Y UN VEHICULO QUE CONTIENE NO MAS DE 0,5% DE UN COMPUESTO SELECCIONADO DE ACIDO 5-(4-FLUOROFENIL)-2,3-DIHIDRO-ß,Ô-DIHIDROXI-3-(1-METILETIL)-2-OXO-4-FENIL-3-[(FENILAMINO)-CARBONIL]-1H-PIRROLO-1-HEPTANOICO, ENTRE OTROS. LA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE ANGINA DE PECHO, ATEROSCLEROSIS, HIPERTENSION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30913301P | 2001-07-31 | 2001-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030324A1 true PE20030324A1 (es) | 2003-04-03 |
Family
ID=23196829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000666A PE20030324A1 (es) | 2001-07-31 | 2002-07-25 | Composiciones farmaceuticas de amlodipina y atorvastatina |
Country Status (46)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6524615B2 (en) * | 2001-02-21 | 2003-02-25 | Kos Pharmaceuticals, Incorporated | Controlled release pharmaceutical composition |
| SI1771455T1 (sl) * | 2004-07-16 | 2016-09-30 | Lek Pharmaceuticals D.D. | Oksidacijski razgradni produkti atorvastatin kalcija |
| ES2263407T1 (es) * | 2004-09-28 | 2006-12-16 | Teva Pharmaceutical Industries Ltd | Procedimiento para la preparacion de formas de atorvastatina calcica sustancialmente libres de impurezas. |
| US8367105B2 (en) | 2004-11-10 | 2013-02-05 | Teva Pharmaceutical Industries, Ltd. | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
| WO2006059217A1 (en) * | 2004-12-01 | 2006-06-08 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine besylate and processes for their preparation |
| US20080305158A1 (en) * | 2004-12-28 | 2008-12-11 | Ranbaxy Laboratories Limited | Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine |
| MX2007011119A (es) * | 2005-03-15 | 2007-11-14 | Lupin Ltd | Composiciones farmaceuticas de amlodipino y benazepril. |
| EP2000137B1 (en) * | 2006-03-29 | 2015-10-21 | Kowa Company, Ltd. | Triglyceride-lowering agent and hyperinsulinism-ameliorating agent |
| DE102006033723A1 (de) * | 2006-07-21 | 2008-01-24 | Bayer Technology Services Gmbh | Formulierungen von Multikompartimenten-Granulaten für Wirkstoffe |
| KR100793321B1 (ko) * | 2006-11-29 | 2008-01-11 | 사회복지법인 삼성생명공익재단 | 후각장애 치료 및 예방용 조성물 |
| CN101433539A (zh) * | 2007-11-12 | 2009-05-20 | 北京瑞康医药技术有限公司 | 含有烟酸氨氯地平和他汀类药物的治疗组合物 |
| EP2070520A1 (en) * | 2007-12-11 | 2009-06-17 | LEK Pharmaceuticals D.D. | Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media |
| WO2009116061A2 (en) * | 2008-01-10 | 2009-09-24 | Alkem Laboratories Ltd. | Stable oral pharmaceutical composition comprising atorvastatin |
| EP2165702B1 (en) | 2008-09-17 | 2011-11-16 | Helm AG | Stable and readily dissolved compositions of candesartan cilexetil prepared with wet granulation |
| WO2010036600A1 (en) * | 2008-09-24 | 2010-04-01 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of atorvastatin |
| EP2575757A1 (en) * | 2010-06-03 | 2013-04-10 | Mahmut Bilgic | Water soluble formulation comprising a combination of amlodipine and a statin |
| JP5810166B2 (ja) | 2011-08-26 | 2015-11-11 | 国立大学法人大阪大学 | 糖尿病性心血管合併症の予防・治療剤 |
| JP2013231011A (ja) * | 2012-05-01 | 2013-11-14 | Sawai Pharmaceutical Co Ltd | アトルバスタチン含有医薬組成物およびそれを用いた口腔内崩壊錠 |
| KR20140030505A (ko) * | 2012-08-31 | 2014-03-12 | 한미약품 주식회사 | 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제 |
| KR20140028971A (ko) | 2012-08-31 | 2014-03-10 | 한미약품 주식회사 | 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제 |
| KR101771766B1 (ko) * | 2013-12-30 | 2017-08-28 | 알보젠코리아 주식회사 | 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제 |
| US10350171B2 (en) | 2017-07-06 | 2019-07-16 | Dexcel Ltd. | Celecoxib and amlodipine formulation and method of making the same |
| CN109180701A (zh) * | 2018-09-07 | 2019-01-11 | 中国药科大学 | 一种化合物2016a0c1药物组合物的共无定形物 |
| KR102042626B1 (ko) | 2019-06-26 | 2019-11-11 | 한미약품 주식회사 | 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제 |
| CN111689922B (zh) * | 2020-07-17 | 2022-03-15 | 江西施美药业股份有限公司 | 一种苯磺酸左旋氨氯地平环合杂质的合成方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5149837A (en) * | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5124482A (en) * | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| US5245047A (en) * | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| US5216174A (en) * | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5097045A (en) * | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5248793A (en) * | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5103024A (en) * | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5155251A (en) * | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
| JP3254219B2 (ja) * | 1993-01-19 | 2002-02-04 | ワーナー−ランバート・コンパニー | 安定な経口用のｃｉ−９８１製剤およびその製法 |
| US5385929A (en) * | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
| SI9500173B (sl) * | 1995-05-19 | 2002-02-28 | Lek, | Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo |
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| NZ312907A (en) * | 1995-07-17 | 2000-12-22 | Warner Lambert Co | Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl |
| RO120816B1 (ro) * | 1995-11-02 | 2006-08-30 | Warner-Lambert Company | COMPOZIŢIE FARMACEUTICĂ PE BAZĂ DE INHIBITOR DE ACIL-CoA COLESTEROL O-ACIL-TRANSFERAZEI ŞI INHIBITOR AL REDUCTAZEI HMG-CoA şi UTILIZAREA ACESTEIA |
| GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
| GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| NZ502283A (en) * | 1997-08-29 | 2002-05-31 | Pfizer Prod Inc | Cardiovascular therapy comprising amlodipine and a statin compound in amounts that are synergistically effective |
| KR100539644B1 (ko) * | 1997-11-25 | 2005-12-29 | 워너-램버트 캄파니 엘엘씨 | 지단백질 산화의 억제 |
| KR20020024581A (ko) * | 1999-04-23 | 2002-03-30 | 알 프레스톤 메이슨 | 암로디핀과 아톨바스타틴의 시너지효과 |
| HN2000000050A (es) * | 1999-05-27 | 2001-02-02 | Pfizer Prod Inc | Sal mutua de amlodipino y atorvastatina |
| WO2002011723A1 (en) * | 2000-08-04 | 2002-02-14 | Mason R Preston | Synergistic effect of amlodipine and atorvastatin |
-
2002
- 2002-07-25 US US10/202,706 patent/US20030114497A1/en not_active Abandoned
- 2002-07-25 PE PE2002000666A patent/PE20030324A1/es not_active Application Discontinuation
- 2002-07-26 NI NI200200095A patent/NI200200095A/es unknown
- 2002-07-26 GT GT200200158A patent/GT200200158A/es unknown
- 2002-07-29 KR KR1020067008620A patent/KR100674762B1/ko not_active Expired - Fee Related
- 2002-07-29 AT AT02751483T patent/ATE385793T1/de not_active IP Right Cessation
- 2002-07-29 HN HN2002000198A patent/HN2002000198A/es unknown
- 2002-07-29 EP EP07110366A patent/EP1852116A1/en not_active Withdrawn
- 2002-07-29 MY MYPI20022844A patent/MY137519A/en unknown
- 2002-07-29 BR BR0211548-4A patent/BR0211548A/pt not_active Withdrawn
- 2002-07-29 EA EA200400028A patent/EA006998B1/ru not_active IP Right Cessation
- 2002-07-29 CN CNA2007101601072A patent/CN101185646A/zh active Pending
- 2002-07-29 RS YU5304A patent/RS5304A/sr unknown
- 2002-07-29 UA UA20031212503A patent/UA79750C2/uk unknown
- 2002-07-29 EP EP02751483A patent/EP1411923B1/en not_active Expired - Lifetime
- 2002-07-29 AR ARP020102852A patent/AR034925A1/es not_active Application Discontinuation
- 2002-07-29 MX MXPA04000270A patent/MXPA04000270A/es active IP Right Grant
- 2002-07-29 HU HU0401569A patent/HUP0401569A2/hu unknown
- 2002-07-29 JP JP2003516513A patent/JP4020863B2/ja not_active Expired - Fee Related
- 2002-07-29 SG SG200601276-9A patent/SG143982A1/en unknown
- 2002-07-29 IL IL15944002A patent/IL159440A0/xx unknown
- 2002-07-29 NZ NZ530247A patent/NZ530247A/en unknown
- 2002-07-29 OA OA1200400009A patent/OA13300A/en unknown
- 2002-07-29 PT PT02751483T patent/PT1411923E/pt unknown
- 2002-07-29 ES ES02751483T patent/ES2298381T3/es not_active Expired - Lifetime
- 2002-07-29 CN CNA028150406A patent/CN1617717A/zh active Pending
- 2002-07-29 AU AU2002355680A patent/AU2002355680B2/en not_active Ceased
- 2002-07-29 AP APAP/P/2004/002963A patent/AP1745A/en active
- 2002-07-29 CA CA002444554A patent/CA2444554C/en not_active Expired - Fee Related
- 2002-07-29 KR KR10-2004-7001522A patent/KR20040032148A/ko not_active Ceased
- 2002-07-29 DK DK02751483T patent/DK1411923T3/da active
- 2002-07-29 GE GE5399A patent/GEP20063926B/en unknown
- 2002-07-29 WO PCT/IB2002/002988 patent/WO2003011283A1/en active IP Right Grant
- 2002-07-29 DE DE60225014T patent/DE60225014T2/de not_active Expired - Fee Related
- 2002-07-29 PL PL02368519A patent/PL368519A1/xx not_active Application Discontinuation
- 2002-07-30 UY UY27402A patent/UY27402A1/es not_active Application Discontinuation
- 2002-07-30 PA PA20028551701A patent/PA8551701A1/es unknown
- 2002-07-30 SV SV2002001189A patent/SV2003001189A/es active IP Right Grant
- 2002-07-30 DO DO2002000445A patent/DOP2002000445A/es unknown
-
2003
- 2003-12-22 IS IS7089A patent/IS7089A/is unknown
- 2003-12-31 CO CO03113785A patent/CO5540287A2/es not_active Application Discontinuation
-
2004
- 2004-01-06 CR CR7219A patent/CR7219A/es not_active Application Discontinuation
- 2004-01-21 MA MA27495A patent/MA27052A1/fr unknown
- 2004-01-22 HR HR20040067A patent/HRP20040067A2/xx not_active Application Discontinuation
- 2004-01-27 ZA ZA200400659A patent/ZA200400659B/en unknown
- 2004-01-29 NO NO20040405A patent/NO20040405L/no not_active Application Discontinuation
- 2004-01-30 EC EC2004004965A patent/ECSP044965A/es unknown
- 2004-01-30 TN TNP2004000022A patent/TNSN04022A1/fr unknown
- 2004-10-19 US US10/968,314 patent/US20050107446A1/en not_active Abandoned
-
2007
- 2007-02-14 JP JP2007034002A patent/JP2007153908A/ja not_active Withdrawn
- 2007-08-01 JP JP2007200684A patent/JP2007314566A/ja not_active Withdrawn
-
2008
- 2008-03-17 CY CY20081100299T patent/CY1107245T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030324A1 (es) | Composiciones farmaceuticas de amlodipina y atorvastatina | |
| MEP33708A (hr) | Farmaceutske smješe koje obuhvataju inhibitor hmg coa reduktaze | |
| UY24816A1 (es) | Sulfonamidas agonistas de prostaglandinas para la prevención y restauración de la masa ósea | |
| EA200500891A1 (ru) | Фармацевтические композиции, содержащие щелочные или соответственно кислые лекарственные соединения, поверхностно-активное вещество и физиологически приемлемую водорастворимую кислоту или соответственно основание | |
| EA200000062A1 (ru) | Фармацевтические композиции, содержащие шипучую кислотно-основную пару | |
| UA44254C2 (uk) | Похідні 4-(заміщеного феніламіно)хіназоліну, спосіб їх одержання, спосіб лікування і фармацевтична композиція | |
| IS4337A (is) | Ný lyfjablanda sem inniheldur ACE-blokkarann ramipríl og díhýdrópýridín efnasamband | |
| EA200400471A1 (ru) | Оральная дозированная форма пропиверина | |
| DK0863891T3 (da) | (Methylsulfonyl)phenyl-2-(5H)-furanoner som COX2-inhibitorer | |
| ATE500818T1 (de) | Kalziumatorvastatin enthaltende arzneiformulierung | |
| DE50110049D1 (de) | Magnesium-ammonium-phosphat-zemente, deren herstellung und verwendung | |
| DK1140918T3 (da) | Thrombininhibitorer | |
| TR200101470T2 (tr) | Farmasötik bileşim terkipleri. | |
| PA8559401A1 (es) | Sales de acido succinico de 5,7,14-triazatetraciclo (10.3.1.0 2,11.0 4, 9)-hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas. | |
| UY24308A1 (es) | Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol, para administracion oral | |
| BR0209283A (pt) | Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme | |
| RS50104B (sr) | Nova oralna formulacija za 5-th4 agoniste ili antagoniste | |
| EA200000142A1 (ru) | Твердый состав для снижения разрушения зубов | |
| ATE489940T1 (de) | Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen | |
| HN2000000075A (es) | Profarmacos mutuos amlodipino y atorvastatina | |
| RU2003124299A (ru) | Фармацевтические составы, обладающие антибиотической активностью | |
| NO994395L (no) | Stabilt, fast preparat som inneholder vitamin D3 og trikalsiumfosfat | |
| ATE314349T1 (de) | Pyroglutaminsäure-salz von amlodipin | |
| EA200602187A1 (ru) | Фармацевтическая композиция и способ её получения | |
| AR008764A1 (es) | Sales hidratadas de n,n'-diacetilcistina, proceso para su preparacion, y composiciones terapeuticas que comprenden a dichas sales como ingredienteactivo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |